Hyperlipidemia
📧 Sign up to get email alerts when something new happens for Hyperlipidemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2015-05-22First-in-class treatment to lower cholesterol
EMA announces a first-in-class treatment to lower cholesterol, representing a novel mechanism for managing the condition.
-
CLINICAL_TRIALS trial_result · 2015-05-15Clinical Trial Update: Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of PreLipid for hyperlipidemia has completed.
-
CLINICAL_TRIALS trial_result · 2015-05-13Clinical Trial Update: Endothelial Hyperpolarization in Humans [Phase 2]
Phase 2 clinical trial update on endothelial hyperpolarization in humans for hyperlipidemia; study terminated with results posted in 2015.
-
CLINICAL_TRIALS research · 2015-05-01Clinical Trial Update: Cilostazol-Simvastatin Drug Interaction Study [Phase 1]
This document reports an ongoing Phase 1 study evaluating potential drug interaction between cilostazol and simvastatin, sponsored by Ajou U…
-
FDA approval · 2015-04-28FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Quallent)
FDA approved a supplemental application for atorvastatin calcium (Quallent).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-04-22Clinical Trial Update: Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. [Phase 3]
Phase 3 study comparing the anti-atherosclerotic effect of torcetrapib added to atorvastatin versus atorvastatin alone has completed.
-
CLINICAL_TRIALS withdrawal · 2015-04-22Clinical Trial Update: A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia [Phase 1]
A pilot Phase 1 trial evaluating vitamin D for relief of statin-associated myalgia in patients with hyperlipidemia has been withdrawn.
-
FDA approval · 2015-04-17FDA Approved: FENOFIBRIC ACID — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved a supplemental application for fenofibric acid from Amneal Pharmaceuticals of New York LLC, resulting in a change to its ap…
-
FDA approval · 2015-04-15FDA Approved: PRAVASTATIN SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Pravastatin Sodium submitted by Aurobindo Pharma Limited, approving this generic statin product.
-
CLINICAL_TRIALS research · 2015-04-15Clinical Trial Update: Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia
This clinical trial update describes investigating whether CETP deficiency influences atherosclerosis in patients with hyperalphalipoprotein…
-
CLINICAL_TRIALS trial_result · 2015-04-07Clinical Trial Update: From Research to Practice - Lipid Management for Low HDL-Cholesterol [NA]
A completed VA-sponsored clinical trial update on lipid management for individuals with low HDL-cholesterol and its implications for clinica…
-
CLINICAL_TRIALS trial_result · 2015-04-07Clinical Trial Update: Community Based Multiple Risk Factors Intervention Strategy [Phase 4]
This Phase 4 community-based trial evaluating a multi-risk-factor intervention for hypertension, diabetes mellitus, and hyperlipidemia has c…
-
FDA approval · 2015-04-06FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Quallent)
The FDA approved a supplemental application for atorvastatin calcium from Quallent, granting updated regulatory approval for this generic st…
-
CLINICAL_TRIALS trial_result · 2015-04-03Clinical Trial Update: Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol [Phase 4]
A Phase 4 study comparing Welchol (colesevelam) plus TriCor (fenofibrate) to TriCor alone in patients with hypercholesterolemia and hyperlip…
-
CLINICAL_TRIALS withdrawal · 2015-03-24Clinical Trial Update: Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors [Phase 4]
Phase 4 trial evaluating ezetimibe/simvastatin and MK0524A in mixed hyperlipidemia with multiple risk factors was withdrawn.
-
FDA approval · 2015-03-23FDA Approved: AMLODIPINE AND ATORVASTATIN — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for the fixed-dose combination of amlodipine and atorvastatin, manufactured by Prasco Laboratories. …
-
CLINICAL_TRIALS trial_result · 2015-03-12Clinical Trial Update: A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism [NA]
A 12-week, three-period trial evaluated the effects of a dietary supplement on lipid metabolism in individuals with hyperlipidemia; the stud…
-
CLINICAL_TRIALS trial_result · 2015-03-10Clinical Trial Update: Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose [NA]
A completed clinical trial studying how glucose and fructose regulate intestinal and hepatic lipoprotein production in hyperlipidemia.
-
CLINICAL_TRIALS trial_result · 2015-02-25Clinical Trial Update: A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED) [Phase 1]
The Phase 1 study MK-0859-011 in patients with primary hypercholesterolemia or mixed hyperlipidemia has completed; this update confirms the …
-
FDA approval · 2015-02-17FDA Approved: AMLODIPINE AND ATORVASTATIN — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for a generic fixed-dose combination tablet of amlodipine besylate and atorvastatin calcium (AML…
-
CLINICAL_TRIALS trial_result · 2015-02-02Clinical Trial Update: Financial Incentives for Medication Adherence [NA]
A completed clinical trial from Boston Medical Center evaluated whether financial incentives improve adherence to medications in patients wi…
-
CLINICAL_TRIALS trial_result · 2014-12-15Clinical Trial Update: Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia [Phase 3]
Phase 3 trial reports on the efficacy and safety of a fixed-dose combination of valsartan 160 mg and rosuvastatin 20 mg in patients with hyp…
-
CLINICAL_TRIALS trial_result · 2014-12-03Clinical Trial Update: Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin [Phase 4]
Phase 4 trial assessing how bariatric surgery alters the metabolism and absorption of atorvastatin in individuals with morbid obesity.
-
CLINICAL_TRIALS research · 2014-12-02Clinical Trial Update: Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders [NA]
A completed clinical trial update examining baseline physiology in carriers of a gene variant associated with high risk of cardiovascular an…
-
FDA approval · 2014-12-01FDA Approved: LOVASTATIN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for Lovastatin by Lupin Pharmaceuticals, Inc., resulting in regulatory approval related to the gener…